Good evening, and I would like to let you know that today's episode about this FDA alert,

it actually comes with a companion episode that I published over on my other new YouTube channel,

which is called Primetime. And that other episode, well, it's about the topic of this new

industry that's popping up over in Silicon Valley, namely designer babies, meaning people who

are mapping out the DNA of their embryos, choosing which character traits they want to keep,

and then discarding the ones they don't. And if you want to know what they actually do with

all of the embryos that they wind up not wanting, well, check out that other episode.

I'll throw a link to it down in the description box below.

And of course, if you choose, subscribe to that channel as well.

Now, moving along to today's topic, just earlier this week on Monday, August 25th, the FDA came out with an announcement, telling the public

that they have actually officially suspended their approval for a certain vaccine. Quote,

the FDA Center for Biologics Evaluation and Research, otherwise known as the C-B-E-R, has suspended

the Biologics license for Valneva Austria- GMBH's I-X-Chic.

Okay, I'm sorry about that. That was a bit of a word salad. Basically, I-X-Chicchik, or I-Chic

is the brand name of the vaccine, whereas Valneva is the France-based manufacturer.

And I-X-Chic is a vaccine for Chikungunya, which is a mosquito-borne disease.

And this particular vaccine, it was initially approved by the FDA to be administered here in the

U.S. back in November of 2023. It was actually fast-tracked in the FDA under what's known as

their accelerated approval pathway, their AAP. That's basically the mechanism that the FDA uses to speed up the availability of both vaccines

and drugs for any illness that's both serious as well as currently untreated.

And Chukungunya, it fit that bill and therefore the FDA approved that vaccine while they

continue to collect further data.

...